Environmental Testing — Apply environmental testing requirements to compounding area compliance decisions

The practice of sterile compounding in pharmacy has always carried inherent risks, yet for decades the profession lacked enforceable, standardized environmental monitoring requirements. Contamination events involving compounded sterile preparations (CSPs) caused patient morbidity and mortality, prompting federal and state regulatory bodies to develop rigorous testing frameworks. The evolution of these standards reflects a broader shift in pharmacy practice from craft-based preparation to quality-system-driven manufacturing, where environmental testing serves as a primary safeguard against microbial contamination and particulate exposure.

The central question driving environmental testing regulation is straightforward yet critical: how can a pharmacy objectively demonstrate that its compounding environment is safe enough to produce sterile preparations for patient use? Environmental testing provides the measurable, reproducible data that answers this question, and pharmacists must understand how to interpret these results when making compliance decisions about whether a compounding area meets the standards necessary to protect patients.

Environmental testing in compounding pharmacy rests on the principle that a controlled environment can be characterized, monitored, and maintained through systematic measurement of both viable particles (living microorganisms) and nonviable particles (inert particulate matter of defined sizes). The regulatory framework established by USP General Chapter <797> defines the ISO classifications, sampling methods, frequencies, and action levels that pharmacies must meet. These principles apply to all areas where sterile compounding occurs, from primary engineering controls (PECs) such as laminar airflow workbenches to the broader secondary engineering controls (SECs) that house them.

The nested architecture depicted in the diagram is foundational to understanding how environmental testing maps to compliance decisions. Air cleanliness improves as one moves inward from the ante area to the buffer area to the PEC, and environmental testing must verify this gradient. Nonviable particle counts are measured using a laser particle counter that draws a defined volume of air and categorizes particles by size. Viable air sampling uses devices such as an impaction air sampler that directs air onto agar media, which is then incubated to allow any captured organisms to grow into countable colonies. Surface sampling uses contact plates — agar-filled plates pressed directly against surfaces — or moistened swabs when contact plates cannot be applied. Each testing modality contributes a different dimension to the overall compliance picture, and pharmacists must integrate all results when making the determination that a compounding area is or is not fit for use.

Nonviable Particle Monitoring

Nonviable particle monitoring is performed using a calibrated airborne particle counter that draws air through a laser detection chamber. Particles passing through the laser beam scatter light, and the instrument classifies particles into size bins — most critically, ≥ 0.5 µm, since this is the threshold used in ISO classification. Particle counts are performed during both certification (initial and recertification every six months) and during dynamic operating conditions to confirm that the classified environment maintains its designation during actual compounding activities.

Viable Sampling Methods

Viable environmental monitoring employs three sampling strategies. Active air sampling uses a volumetric impaction sampler to draw a measured volume of air (typically 1,000 liters for ISO 5 zones) onto trypticase soy agar (TSA) plates. The revised USP <797> requires a two-phase incubation protocol: plates are incubated first at a higher temperature range (approximately 30–35 °C) for the initial portion of the incubation period to promote bacterial growth, then moved to a lower temperature range (approximately 20–25 °C) for the remainder of the incubation period to support recovery of fungal organisms, with a total minimum incubation period of about 7 days before final colony counts are read. Settle plates (passive air sampling) expose open agar plates to the environment for a defined period, collecting organisms that settle by gravity, and are incubated using this same two-phase, minimum 7-day protocol. Surface sampling using contact plates (RODAC plates) or swabs directly assesses microbial contamination of work surfaces, floors, walls, and equipment within the compounding area, with the recovered media incubated under this same protocol. Results from all three methods are expressed in colony-forming units (CFU) and compared to the harmonized action levels defined by USP <797> for each ISO classification.

The revised USP <797> specifies minimum frequencies for each category of environmental testing, and these frequencies differ based on the type of compounding performed. Pharmacies compounding Category 1 CSPs (those assigned a beyond-use date of 12 hours or less at controlled room temperature, or 24 hours or less refrigerated) have somewhat less demanding frequency requirements than pharmacies compounding Category 2 CSPs (those with longer BUDs). Understanding these distinctions is critical for MPJE preparation because state boards of pharmacy routinely test candidates on their ability to apply the correct testing schedule to a given compounding scenario.

Documentation is a legally critical component of environmental testing. Every sampling event must be documented with the date and time of sampling, the specific location sampled, the sampling method and device used, the results obtained (with organism identification if growth is detected), the name of the person performing the sampling, and the disposition of the results relative to action levels. When exceedances occur, the pharmacy must also document the investigation findings, corrective and preventive actions taken, re-sampling results, and the authorization from the designated person to resume compounding. State boards of pharmacy review these records during inspections, and inadequate documentation can result in enforcement actions even if the pharmacy's actual environmental conditions are acceptable.

• ✓ PEC Certification — Must be performed at installation, after relocation, and every 6 months. Includes HEPA filter integrity (DOP or PAO leak testing), total airborne particle counts, airflow velocity, and smoke pattern visualization.
• ✓ Viable Sampling — Minimum monthly for active air sampling in the PEC, buffer area, and ante area. Surface sampling of the PEC interior surfaces at least monthly.
• ✓ Personnel Sampling — Gloved fingertip and thumb sampling initially, then at least every 6 months. Media-fill testing initially and at least annually.
• ✓ Smoke Studies — Dynamic airflow visualization at initial certification, every 6 months during recertification, and whenever changes are made to the room or PEC configuration.

The following scenario illustrates how a pharmacist-in-charge would evaluate environmental monitoring data and make a compliance decision. This type of analysis is representative of questions encountered on the MPJE regarding environmental testing application.

Each environmental testing method has distinct strengths and limitations. Understanding these trade-offs is important for pharmacists because state board inspectors may ask why a particular testing method was chosen or whether additional methods should be employed. The table below compares the primary methods used in compounding environmental monitoring.

Environmental testing under USP <797> represents the foundational layer of compounding quality assurance, but it connects directly to more advanced regulatory concepts that pharmacists encounter as they assume leadership roles or pursue board certification. Understanding these connections is valuable for MPJE preparation because questions frequently bridge between basic monitoring and broader regulatory frameworks.

Looking forward, the pharmacy profession is increasingly moving toward risk-based environmental monitoring approaches. USP <825> (Radiopharmaceuticals) has introduced its own set of environmental monitoring standards tailored to the unique challenges of short-lived radiopharmaceutical compounding. Meanwhile, USP <800> (Hazardous Drugs) intersects with <797> by addressing containment requirements for hazardous drug compounding, where environmental monitoring must also verify negative pressure differentials and containment effectiveness. Pharmacists who master the environmental testing framework in <797> will find that these related standards build logically upon the same foundational principles of air quality classification, viable sampling, and corrective action protocols.